GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

Betsy Goodfellow | November 27, 2023 | News story | Medical Communications |  Blenrep, GSK, Oncology, clinical trial, multiple myeloma 

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed Blenrep (belantamab mafodotin) as a second line treatment for relapsed or refractor multiple myeloma.

The trial met the primary endpoint of progression-free survival (PFS) as well as demonstrating that Blenrep combined with bortezomib plus dexamethasone (BorDex) significantly extended time to disease progression or death compared to standard-of-care treatment with daratumumab plus BorDex.

The safety and tolerability of the Blenrep treatment regimen remained consistent with the known safety profile of all drugs used in the trial.

Hesham Abdullah, senior vice president, global head Oncology, R&D at GSK, commented: “Patients with multiple myeloma need treatment options after first relapse that are efficacious, readily accessible and have novel mechanisms of action. We are particularly encouraged by the potential for belantamab mafodotin when combined with BorDex to address high unmet need in relapsed/refractory multiple myeloma, given the head-to-head comparison with the daratumumab-based standard of care regimen.”

Results from this interim analysis are expected to be presented at an upcoming scientific meeting as well as being shared with the relevant health authorities.

Betsy Goodfellow